NCT03865082: A reported trial by Idera Pharmaceuticals, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03865082 |
|---|---|
| Title | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 29, 2019 |
| Completion date | March 31, 2022 |
| Required reporting date | March 31, 2023, midnight |
| Actual reporting date | Dec. 1, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |